pSivida initiates R&D collaboration with University of South Australia
pSivida Limited announced that it has entered into a research and development collaboration with the Ian Wark Research Institute ("The Wark(tm)") at the University of South Australia to evaluate the potential of its BioSilicon(tm) platform for the delivery of protein- and peptide-based therapeutics.
pSivida's promising preliminary investigations using BioSilicon(tm) have indicated its utility for the delivery of biopharmaceuticals, including its potential for the development of new controlled release formulations of existing marketed therapeutics. The collaboration with the Wark(tm), which is initially for a period of six months with the possibility of further extension, will investigate further this potential application of BioSilicon(tm) and will form the basis of future R&D programmes in this important area.
pSivida's Managing Director, Gavin Rezos, said, "The Ian Wark Research Institute is one of the leading science and technology centres in Australia and I am very pleased that we have initiated this exciting R&D project with them. The R&D expertise and track record of the Wark(tm) in the areas of nanotechnology, biomaterials and drug delivery means that we have an excellent opportunity to advance the development of our unique BioSilicon(tm) platform as a potential solution to the current problems surrounding the delivery of biopharmaceuticals."
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
